An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Academic Article uri icon

Overview

abstract

  • Twenty-two women (17 pre- and 5 postmenopausal) with nodepositive, stage II breast carcinoma were treated with adjuvant chemotherapy consisting of 16 weeks of intensive CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) administered in the original dose and schedule of the "Cooper regimen," followed by four monthly, 3-day cycles of escalating doxorubicin. Toxicity was related primarily to myelosuppression associated with the doxorubicin component of the treatment regimen. All patients recovered without sequelae. No patient developed significant cardiac toxicity. With a median follow-up of 43 months (range: 20-89 months), two postmenopausal patients and one premenopausal patient have relapsed at 35, 37, and 42 months, respectively. By Kaplan-Meier survival analysis, there is an 80.5% chance of disease-free survival to 42 months. The feasibility of administering adjuvant CMFVP followed by intensive doxorubicin has been established. The pilot results warrant comparative trial with the best of current regimens.

publication date

  • January 1, 1993

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms

Identity

Scopus Document Identifier

  • 0027463665

Digital Object Identifier (DOI)

  • 10.3109/07357909309020254

PubMed ID

  • 8422597

Additional Document Info

volume

  • 11

issue

  • 1